Prostate Cancer Clinical Trials in Salt Lake City

Showing 201-220 of 303 trials

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829

This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253. The study will be conducted in 2 parts: part 1 (dose escalation) and part 2 (dose expansion).

Metastatic Castrate-resistant Prostate CancerAdenocarcinoma, Prostate

Tracon Pharmaceuticals Inc.72 participantsStarted May 2017

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Santa Monica, California, United States +2 more locations

COMPLETEDPhase 1< 1 mile

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

NCT01338831

The purpose of this first multi-dose study in cancer patients is to determine the maximum tolerated dose (MTD) or recommended phase II dose (RP2D), characterize the safety, tolerability and pharmacokinetics profile. Once the MTD has been established and/or a RP2D chosen, the study will enroll patients into the expansion portion of the study.

Castration-resistant Prostate CancerMetastatic Breast CancerUterine Leiomyoma

Novartis Pharmaceuticals73 participantsStarted Sep 2011

Boston, Massachusetts, United States • New Brunswick, New Jersey, United States • Philadelphia, Pennsylvania, United States +6 more locations

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

Prostate Cancer Trials in Other Cities

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

Prostate Cancer Intervention Versus Observation Trial (PIVOT)

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

Genetic Analysis of Hereditary Prostate Cancer

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Other Conditions in Salt Lake City